J. Yale, G. Bakris, Bertrand Cariou, Dennis K. Yue, Elias David-Neto, Liwen Xi, K. Figueroa, E. Wajs, K. Usiskin, G. Meininger
2013.3.28DIABETES OBESITY & METABOLISM
tlooto Summary
This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease.
Abstract
Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].
Citation format
YALE, J., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. DIABETES OBESITY & METABOLISM, 2013, 15: 463–473.